bioAffinity Technologies, Inc. released a case study on July 23, 2025, showcasing CyPath® Lung's capability to detect a Stage 1A neuroendocrine tumor in a patient's lung. This tumor was not identified by standard imaging and other adjuvant diagnostic tools.
The patient, with a history of smoking, presented with a suspicious nodule on a CT scan. When other diagnostic methods proved inconclusive, the CyPath® Lung test provided a 'likely cancer' result, prompting further investigation.
This led to a confirmed diagnosis of a neuroendocrine tumor at an early stage. The case highlights CyPath® Lung's unique diagnostic power in complex scenarios, potentially enabling earlier and more accurate detection of difficult-to-diagnose lung cancers, which can significantly improve patient outcomes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.